NCT05180240Phase 2Completed

Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis

Study sponsor: Cardiol Therapeutics Inc. · CRDL

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-01-31Actual

Enrollment · participants109Actual

Source updated2026-06-17Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-22 · 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: ~~extracellular~~ ~~volume~~ (ECV) Measure: Global ~~longitudinal~~ Strain (GLS)

+ After

Measure: Extracellular Volume (ECV) Measure: Global Longitudinal Strain (GLS)

Check registry source

Study details

Conditions studied

Acute Myocarditis

Treatments or interventions studied

CardiolRxDrugAlso known as Cannabidiol

Primary outcomes · main study measures

Read the study measures

measure: Extracellular Volume (ECV); description: Change of ECV from baseline at 12 weeks, measured by cardiac Cardiac MRI. ECV is measuring the degree of edema and fibrosis. The unit of measure was percentage. It was the percentage of myocardial tissue that is extracellular space (i.e. fraction of the myocardium occupied by extracellular matrix and interstitial fluid).; timeFrame: 12 weeks post randomization; measure: Global Longitudinal Strain (GLS); description: The outcome was the change in GLS from baseline at 12 weeks, measured by cardiac Cardiac MRI. GLS is a predictor of cardiac function. The unit of measure is percentage. It is the percent change in myocardial length relative to its original (end-diastolic) length along the long axis. Longitudinal strain during systole is usually negative, because the ventricle shortens; normal peak GLS in healthy adults is around -20% (i.e., 20% shortening relative to original length); timeFrame: 12 weeks post randomization

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history